Phaseline

Companies › Citryll

Citryll: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 2; Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CIT-013–Phase 2Rheumatoid Arthritis; Hidradenitis Suppurativa (HS)Apr 2027
[89Zr]Zr-CIT
Radiolabeled monoclonal antibody imaging agent targeting neutrophil extracellular traps (N
NONEPhase 2RA–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06567470CIT-013Phase 2Rheumatoid ArthritisImmunologyJul 2026
NCT07147959[89Zr]Zr-CITPhase 2RAImmunologyJul 2026
NCT06993233CIT-013Phase 2Hidradenitis Suppurativa (HS)ImmunologyApr 2027

Targets

NONE (1)

Companies with the same targets

–

Companies built like this

Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines OrthoTrophix Resolve Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.